Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-05-19Clinical Trial Update: DTI in Children With Multiple Sclerosis [NA]
A clinical trial update examining diffusion tensor imaging (DTI) in children with multiple sclerosis, including relapsing-remitting MS and c…
-
CLINICAL_TRIALS trial_result · 2016-05-12Clinical Trial Update: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis [Phase 4]
A Phase 4 study (PACE) evaluating physical activity in patients with relapsing-remitting multiple sclerosis treated with fingolimod was term…
-
CLINICAL_TRIALS research · 2016-05-12Clinical Trial Update: Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
A clinical trial update examining how polymorphisms in interleukin, glypican, and HLA genes influence treatment response in relapsing-remitt…
-
CLINICAL_TRIALS trial_result · 2016-05-11Clinical Trial Update: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) [Phase 2]
Phase 2 clinical trial of Plovamer Acetate for relapsing-remitting multiple sclerosis was terminated; results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome [Phase 2]
A Phase 2 trial evaluating Trichuris suis ova (TSO) for relapsing-remitting multiple sclerosis and clinically isolated syndrome has been ter…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-04-29Clinical Trial Update: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS [Phase 4]
Phase 4 evaluation of autonomic nervous system effects during the first dose of 0.5 mg fingolimod (Gilenya) in relapsing-remitting multiple …
-
CLINICAL_TRIALS trial_result · 2016-04-28Clinical Trial Update: Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis [Phase 3]
This clinical trial update reports on a Phase 3 study evaluating the safety and efficacy of pravastatin in relapsing-remitting multiple scle…
-
CLINICAL_TRIALS withdrawal · 2016-04-25Clinical Trial Update: Brimonidine Tartrate for the Treatment of Injection Related Erythema [Phase 4]
A Phase 4 study evaluating brimonidine tartrate for injection-related erythema in relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-04-13Clinical Trial Update: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]
A Phase 3 placebo-controlled study of BG00012 (dimethyl fumarate) in pediatric relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: Extension Study of MT-1303 [Phase 2]
This clinical trial update notes the completion of the Phase 2 extension study of MT-1303 for Relapsing-remitting Multiple Sclerosis, sponso…
-
CLINICAL_TRIALS trial_result · 2016-04-08Clinical Trial Update: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis [Phase 2]
Phase 2 cooperative trial evaluating abatacept in relapsing-remitting multiple sclerosis has completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-04-08Clinical Trial Update: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
Biogen-sponsored trial (NCT02323269) evaluates dimethyl fumarate for relapsing-remitting multiple sclerosis, focusing on patient-reported ou…
-
CLINICAL_TRIALS withdrawal · 2016-04-06Clinical Trial Update: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 2]
Phase 2 proof-of-concept trial evaluating RNS60 for Relapsing-Remitting Multiple Sclerosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS [Phase 1]
This Phase 1 study evaluates autologous mesenchymal stem cell transplantation in people with relapsing-remitting, secondary progressive, or …
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis [Phase 2]
Open-label extension of Opexa Therapeutics' TERMS Phase 2 trial for relapsing forms of multiple sclerosis was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2016-03-02Clinical Trial Update: High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients [NA]
This trial compares high-dose oral vitamin D3 versus intramuscular vitamin D3 supplementation in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS withdrawal · 2016-02-29Clinical Trial Update: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
A clinical trial comparing Rebif (interferon beta-1a) with Tecfidera (dimethyl fumarate) for six-month outcomes in relapsing-remitting multi…
-
CLINICAL_TRIALS trial_result · 2016-01-29Clinical Trial Update: Worms for Immune Regulation of Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating helminth-based immunomodulation for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Extension Phase 2 study assessing safety and efficacy of Natalizumab in Japanese participants with Relapsing-Remitting Multiple Sclerosis; r…
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: Safety and Tolerability of Glatiramer Acetate [Phase 3]
Phase 3 trial evaluating the safety and tolerability of glatiramer acetate in Relapsing-Remitting Multiple Sclerosis has completed with resu…
-
CLINICAL_TRIALS withdrawal · 2015-12-28Clinical Trial Update: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis [Phase 4]
A Phase 4 trial evaluating the onset of efficacy of dimethyl fumarate (BG00012) in relapsing-remitting multiple sclerosis has been withdrawn…
-
CLINICAL_TRIALS research · 2015-12-02Clinical Trial Update: Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS [NA]
The trial update describes development of a talk therapy protocol designed to help patients with Relapsing-remitting Multiple Sclerosis make…
-
CLINICAL_TRIALS trial_result · 2015-12-02Clinical Trial Update: Development of a Motivational Intervention to Improve Treatment Adherence in MS [NA]
A completed clinical trial evaluating a motivational intervention to improve treatment adherence in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating allogeneic human umbilical cord mesenchymal stem cells with Liberation Therapy for relapsing-remitting m…
-
CLINICAL_TRIALS research · 2015-10-28Clinical Trial Update: A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS [Phase 1, Phase 2]
This document updates on a Phase 1/2 study evaluating allogeneic human umbilical cord-derived mesenchymal stem cells with Liberation Therapy…